Anxiety disorders are a prevalent and disabling condition. Because of high rates of treatment resistance, there is interest in new pharmacological treatment options such as second-generation antipsychotics. This systematic review evaluated the efficacy and tolerability of second-generation antipsychotics in the treatment of anxiety disorders. We found eleven randomised placebo-controlled trials, comparing quetiapine, olanzapine and risperidone with placebo and antidepressants. The vast majority of the available data was on quetiapine (> 3000 participants). Participants with generalised anxiety disorder responded significantly better to quetiapine than to placebo, measured as a reduction in the Hamilton Anxiety Scale (HAM-A). Participants treated with quetiapine were more likely to drop out due to adverse events, to gain weight, to suffer from sedation or to suffer from extrapyramidal side effects. The evidence on the other second-generation antipsychotics is currently too limited to draw any conclusions.
- Do they agree? How parents and professionals perceive the support provided to persons with profound intellectual and multiple disabilities
- Maternal depression and intimate partner violence exposure: Longitudinal analyses of the development of aggressive behavior in an at-risk sample
- Exploring rates of transgender individuals and mental health concerns in an online sample
- Disability and the meaning of reproductive liberty
- Tobacco-nicotine education and training for health-care professional students and practitioners: a systematic review
Category Specific RSS